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Abstract ͵ͺ  ͵ͻ By meta-analyzing rare coding variants in whole-exome sequences of ͶͲ Ͷ,ͳ͵͵ schizophrenia cases and ͻ,ʹ͹Ͷ controls, de novo mutations in ͳ,Ͳ͹͹ trios, Ͷͳ and copy number variants from ͸,ͺͺʹ cases and ͳͳ,ʹͷͷ controls, we show that Ͷʹ individuals with schizophrenia carry a significant burden of rare damaging Ͷ͵ variants in ͵,Ͷͺͺ genes previously identified as having a near-complete ͶͶ 
depletion of loss-of-function variants. )n schizophrenia patients who also have Ͷͷ intellectual disability, this burden is concentrated in risk genes associated with Ͷ͸ neurodevelopmental disorders. After excluding known neurodevelopmental Ͷ͹ disorder risk genes, a significant rare variant burden persists in other loss-of-Ͷͺ function intolerant genes, and while this effect is notably stronger in Ͷͻ schizophrenia patients with intellectual disability, it is also seen in patients who ͷͲ do not have intellectual disability. Together, our results show that rare damaging ͷͳ variants contribute to the risk of schizophrenia both with and without ͷʹ intellectual disability, and support an overlap of genetic risk between ͷ͵ schizophrenia and other neurodevelopmental disorders.  ͷͶ  ͷͷ 
Introduction ͷ͸ ͷ͹ Schizophrenia is a common and debilitating psychiatric illness ͷͺ characterized by positive symptoms ȋhallucinations, delusions, disorganized ͷͻ speech and behaviourȌ, negative symptoms ȋsocial withdrawal and diminished ͸Ͳ emotional expressionȌ, and cognitive impairment that result in social and ͸ͳ occupational dysfunctionͳ,ʹ. Operational diagnostic criteria for the disorder as ͸ʹ described in the DSM-V require the presence of at least two of the core ͸͵ symptoms over a period of six months with at least one month of active ͸Ͷ symptoms͵. )t is increasingly recognized that current categorical psychiatric ͸ͷ classifications have a number of shortcomings, in particular that they overlook ͸͸ the increasing evidence for etiological and mechanistic overlap between ͸͹ psychiatric disordersͶ.  ͸ͺ  ͸ͻ A diverse range of pathophysiological processes may contribute to the ͹Ͳ clinical features of schizophreniaͷ. )ndeed, previous studies have suggested a ͹ͳ number of hypotheses about schizophrenia pathogenesis, including abnormal ͹ʹ pre-synaptic dopaminergic activity͸, postsynaptic mechanisms involved in ͹͵ synaptic plasticity͹, dysregulation of synaptic pruningͺ, and disruption to early ͹Ͷ brain developmentͻ,ͳͲ. This complexity is underpinned by the varied nature of ͹ͷ genetic contributions to risk of schizophrenia. Genome-wide association studies ͹͸ have identified over ͳͲͲ independent loci defined by common ȋminor allele ͹͹ frequency [MAF] > ͳ%Ȍ single nucleotide variants ȋSNVsȌͳͳ, and a recent analysis ͹ͺ determined that more than ͹ͳ% of all one-megabase regions in the genome ͹ͻ contain at least one common risk alleleͳʹ. The modest effects of these variants ͺͲ ȋmedian odds ratio [OR] = ͳ.ͲͺȌ combine to produce a polygenic contribution ͺͳ that explains only a fraction ȋℎଶ = Ͳ.ʹ͹ͶȌ of the overall liabilityͳʹ. )n addition, a ͺʹ number of rare variants have been identified that have far larger effects on ͺ͵ individual risk. These are best exemplified by eleven large, rare recurrent copy ͺͶ number variants ȋCNVsȌ but evidence from whole-exome sequencing studies ͺͷ implies that many other rare coding SNVs and de novo mutations also confer ͺ͸ substantial individual riskͳ͵–ͳ͹. There is growing evidence that some of the same ͺ͹ genes and pathways are affected by both common and rare variants͹,ͳͺ. Pathway ͺͺ analyses of common variants and hypothesis-driven gene set analyses of rare ͺͻ variants have begun to enumerate some of these specific biological processes, ͻͲ including histone methylation, transmission at glutamatergic synapses, calcium ͻͳ channel signaling, synaptic plasticity, and translational regulation by the fragile X ͻʹ mental retardation protein ȋFMRPȌͳͳ,ͳ͵,ͳͶ,ͳͻ,ʹͲ. ͻ͵ 
 ͻͶ )n addition to exploring the biological mechanisms underlying ͻͷ schizophrenia, genetic analyses can also be used to understand its relationship to ͻ͸ other neuropsychiatric and neurodevelopmental disorders. For instance, ͻ͹ schizophrenia, bipolar disorder, and autism ȋASDȌ show substantial sharing of ͻͺ common risk variantsʹͳ,ʹʹ. Sequencing studies of neurodevelopmental disorders ͻͻ suggest that this sharing of genetic risk may extend to rare variants of large ͳͲͲ effect. )n the largest sequencing study of ASD to date, ʹͲ of the Ͷ͸ genes and all ͳͲͳ six CNVs implicated ȋfalse discovery rate [FDR] < ͷ%Ȍ had been previously ͳͲʹ described as dominant causes of developmental disordersʹ͵. Furthermore, an ͳͲ͵ analysis of ͸Ͳ,͹Ͳ͸ whole exomes led by the ExAC consortium identified ͵,ʹ͵Ͳ ͳͲͶ genes with near-complete depletion of protein-truncating variants, and de novo ͳͲͷ loss-of-function ȋLoFȌ mutations identified in individuals with ASD or ͳͲ͸ developmental disorders were concentrated in this set of ǲLoF intolerantǳ ͳͲ͹ genesʹ͵–ʹͷ. Similarly, evidence from rare variants for a broader shared genetic ͳͲͺ etiology between schizophrenia and neurodevelopmental disorders has begun to ͳͲͻ emerge. Analyses of whole-exome data provided support for an enrichment of ͳͳͲ schizophrenia rare variants in intellectual disability genes, and schizophrenia ͳͳͳ cases were also found to have a higher concentration of ultra-rare disruptive ͳͳʹ SNVs in the ExAC LoF intolerant genes compared to controlsͳ͵,ͳ͹,ʹ͸.  ͳͳ͵  ͳͳͶ (owever, the contribution of these rare variants to risk in the wider ͳͳͷ population of individuals diagnosed with schizophrenia, including those without ͳͳ͸ intellectual disability, remains unclear. )ntriguingly, the ͳͳ rare CNVs found to be ͳͳ͹ highly penetrant for schizophrenia also increased risk for intellectual disability ͳͳͺ and other congenital defectsͳ͸,ʹ͹, and more recently, a meta-analysis of whole-ͳͳͻ exome sequence data showed that LoF variants in SETD1A conferred substantial ͳʹͲ risk for both schizophrenia and neurodevelopmental disordersͳͺ. Concurrent ͳʹͳ analyses of autism whole-exome data found that de novo loss-of-function ȋLoFȌ ͳʹʹ mutations identified in ASD probands, particularly those that disrupt genes ͳʹ͵ associated with neurodevelopmental disorders, were disproportionately found ͳʹͶ in individuals with intellectual disabilityʹ͵,ʹͺ. These emerging results raise the ͳʹͷ possibility that rare schizophrenia risk variants may be concentrated in a subset ͳʹ͸ of schizophrenia patients with co-morbid intellectual disability. (ere, we present ͳʹ͹ the one of the largest accumulation of schizophrenia rare variant data to date, ͳʹͺ which we jointly analyze with phenotype data on cognitive function. Using this ͳʹͻ data set, we attempt to identify groups of genes disrupted by schizophrenia rare ͳ͵Ͳ risk variants, and determine if a subset of patients disproportionately carry ͳ͵ͳ these damaging alleles.  ͳ͵ʹ  ͳ͵͵ 
Results ͳ͵Ͷ  ͳ͵ͷ 
Study design ͳ͵͸  ͳ͵͹ To maximize our power to detect enrichment of damaging variants in ͳ͵ͺ schizophrenia cases in groups of genes, we performed a meta-analysis of three ͳ͵ͻ different types of rare coding variant studies: ȋͳȌ high-quality SNV calls from ͳͶͲ whole-exome sequences of Ͷ,ͳ͵͵ schizophrenia cases and ͻ,ʹ͹Ͷ matched ͳͶͳ controls, ȋʹȌ de novo mutations identified in ͳ,Ͳ͹͹ schizophrenia parent-proband ͳͶʹ 
trios ȋFigure ͳȌ, and ȋ͵Ȍ CNV calls from genotyping array data of ͸,ͺͺʹ cases and ͳͶ͵ ͳͳ,ʹͷͷ controls.  The ascertainment of these samples, data production, and ͳͶͶ quality control were described previouslyͳͺ,ʹͻ. All de novo mutations included in ͳͶͷ our analysis had been validated through Sanger sequencing, and stringent ͳͶ͸ quality control steps were performed on the case-control data to ensure that ͳͶ͹ sample ancestry and batch were closely matched between cases and controls ͳͶͺ ȋOnline MethodsȌ.  ͳͶͻ  ͳͷͲ For each data type, we used appropriate methods to test for an excess of ͳͷͳ rare variants ȋFigure ͳ, Online MethodsȌ. )n analyses of case-control SNV data, ͳͷʹ we applied an extension of the variant threshold burden test that corrected for ͳͷ͵ exome-wide differences between cases and controls͵Ͳ. We tested all allele ͳͷͶ frequency thresholds below Ͳ.ͳ% observed in our data, and assessed statistical ͳͷͷ significance by permutation testing. )n analyses of de novo SNV data, we ͳͷ͸ compared the observed number of de novo mutations to random samples from ͳͷ͹ an expected distribution based on a gene-specific mutation rate model to ͳͷͺ calculate an empirical P-value. For both types of whole-exome sequencing data, ͳͷͻ we restricted our analyses to loss-of-function variants. Finally, in analyses of ͳ͸Ͳ case-control CNV data, we used a logistic regression framework that compares ͳ͸ͳ the rate of CNVs overlapping a specific gene set while correcting for differences ͳ͸ʹ in CNV size and number of genes disrupted͹,ͳͻ,͵ͳ. To ensure our model was well ͳ͸͵ calibrated, we restricted our analyses to small deletions and duplications ͳ͸Ͷ overlapping fewer than seven genes with MAF < Ͳ.ͳ% ȋSupplementary Figure ͳ, ͳ͸ͷ Online MethodsȌ.  ͳ͸͸  ͳ͸͹ We tested for an excess of rare damaging variants in schizophrenia ͳ͸ͺ patients in ͳ,͹͸͸ gene sets ȋOnline Methods, Supplementary Table ͳ, and ͳ͸ͻ detailed results belowȌ. Gene set P-values were computed using the three ͳ͹Ͳ methods and variant definitions described above, and then meta-analyzed using ͳ͹ͳ Fisherǯs Method to provide a single P-value for each gene set. Because we gave ͳ͹ʹ each data type equal weight, gene sets achieving significance typically show at ͳ͹͵ least some signal in all three types of data. We observed a marked inflation in the ͳ͹Ͷ quantile-quantile ȋQ-QȌ plot of gene set P-values ȋSupplementary Figure ʹȌ, so ͳ͹ͷ we conducted two analyses to ensure our results were robust and not biased due ͳ͹͸ to methodological or technical artifacts. First, we observed no inflation of P-ͳ͹͹ values when testing for enrichment of synonymous variants in our case-control ͳ͹ͺ and de novo analyses ȋSupplementary Figure ʹȌ. Second, we created random ͳ͹ͻ gene sets by sampling uniformly across the genome, and observed null ͳͺͲ distributions in Q-Q plots regardless of variant class and analytical method ͳͺͳ ȋSupplementary Figure ͵Ȍ. These findings suggested that our methods ͳͺʹ sufficiently corrected for known genome-wide differences in LoF and CNV ͳͺ͵ burden between cases and controls, and other technical confounders like batch ͳͺͶ and ancestry.  ͳͺͷ  ͳͺ͸ 
Rare, damaging schizophrenia variants are concentrated in LoF intolerant genes ͳͺ͹  ͳͺͺ We first tested whether rare schizophrenia risk variants were ͳͺͻ consistently concentrated in genes defined loss-of-function intolerant acrossͳͻͲ study design and variant type. Because some of our schizophrenia exome data ͳͻͳ 
was included in the ExAC database, we focused on the subset of Ͷͷ,͵͹͸ ExAC ͳͻʹ exomes without a known psychiatric diagnosis and that were not present in our ͳͻ͵ study. From this subset, ͵,Ͷͺͺ genes were found to have near-complete ͳͻͶ depletion of such variants, which we defined as the LoF intolerant gene set. We ͳͻͷ found that rare damaging variants in schizophrenia cases were enriched in LoF ͳͻ͸ intolerant genes ȋP < ͵.͸ × ͳͲଵ଴, Table ͳ, Figure ʹȌ, with support in case-control ͳͻ͹ SNVs ȋP < ͷ × ͳͲ଻; OR ͳ.ʹͶ, ͳ.ͳ͸-ͳ.͵ͳ, ͻͷ% C)Ȍ, case-control CNVs ȋP = ͳͻͺ ʹ.͸ × ͳͲସ; OR ͳ.ʹͳ, ͳ.ͳͷ – ͳ.ʹͺ, ͻͷ% C)Ȍ, and de novo mutations ȋP = ͸.͹ × ͳͲଷ; ͳͻͻ OR ͳ.͵͸, ͳ.ͳ – ͳ.͸ͺ, ͻͷ% C)Ȍ.  While this result was consistent with observations ʹͲͲ in intellectual disability and ASDʹͶ,͵ʹ the absolute effect size is smaller ȋe.g. de ʹͲͳ 
novos, Supplementary Figure Ͷ and ͷȌ. We observed no excess burden of rare ʹͲʹ damaging variants in the remaining ͳͶ,͹ͷ͵ genes ȋFigure ʹ, Supplementary ʹͲ͵ Figure ͷȌ. Furthermore, this signal was spread among many different LoF ʹͲͶ intolerant genes: if we rank genes by decreasing significance, the enrichment ʹͲͷ disappears in the case-control SNV analysis ȋP > Ͳ.ͲͷȌ only after the exclusion of ʹͲ͸ the top ͷͲ genes. This suggests that the contribution of damaging rare variants in ʹͲ͹ schizophrenia is not concentrated in just a handful of genes, but instead spread ʹͲͺ across many genes. ʹͲͻ  ʹͳͲ 
Schizophrenia risk genes are shared with other neurodevelopmental disorders ʹͳͳ  ʹͳʹ Given the significant enrichment of rare damaging variants in LoF ʹͳ͵ intolerant genes in developmental disorders, autism and schizophrenia, we next ʹͳͶ asked whether these variants affected the same genes.  We found that autism ʹͳͷ risk genes identified from exome sequencing meta-analysesʹ͵ and genes in which ʹͳ͸ LoF variants are known causes of severe developmental disorders as defined by ʹͳ͹ the DDD study͵͵,͵Ͷ were significantly enriched for rare variants in individuals ʹͳͺ with schizophrenia ȋPASD = ͻ.ͷ× ͳͲ଺; PDD = ʹ.͵× ͳͲ଺; Table ͳ, Online MethodsȌ. ʹͳͻ Previous analyses have shown an enrichment of rare damaging variants in genes ʹʹͲ whose mRNA are bound by FMRP in both schizophrenia and autism͵ͷ,ͳ͵,͵ʹ, so we ʹʹͳ sought to identify further shared biology by testing targets of neural regulatory ʹʹʹ genes previously implicated in autism͵ʹ,͵͸.  We observed enrichment of both ʹʹ͵ such sets: promoter targets of CHD8 ȋP = ͳ.ͳ× ͳͲ଺Ȍ and splice targets of RBFOX ʹʹͶ ȋP = ͳ.͵× ͳͲହȌ ȋTable ͳȌ. We noted that some published gene lists attributed to ʹʹͷ same biological process differed due to choices of assay, cell type, method of ʹʹ͸ sample extraction, and threshold of statistical significance, leading to distinct ʹʹ͹ results in our gene set analyses. For example, we observed a significant ʹʹͺ enrichment in the published FMRP binding gene set based on mouse brain ʹʹͻ data͵͹, but with no signal in one based on a human kidney cell line͵ͺ. ʹ͵Ͳ  ʹ͵ͳ We also tested an additional ͳ,͹ͷͻ gene sets from databases of biological ʹ͵ʹ pathways with at least ͳͲͲ genes, as we lacked power to detect weak ʹ͵͵ enrichments in smaller sets ȋOnline MethodsȌ. We observed enrichment of ʹ͵Ͷ damaging rare variants in schizophrenia cases at FDR q < Ͳ.Ͳͷ in ͵ͷ of these ʹ͵ͷ gene sets ȋSupplementary Table ͳ, ʹȌ. These included previously implicated gene ʹ͵͸ sets, like the NMDA receptor and ARC complexesͳ͵,ͳͶ,͵ͷ,͵͹, as well as novel gene ʹ͵͹ sets, such as genes involved in cytoskeleton ȋGO: ͲͲͲ͹ͲͳͲȌ, chromatin ʹ͵ͺ modification ȋGO:ͲͲͳ͸ͷ͸ͺȌ, and chromatin organization ȋGO: ͲͲͲ͸͵ʹͷȌ. ʹ͵ͻ Furthermore, the gene sets most significantly enriched ȋFDR q < Ͳ.ͲͳȌ for ʹͶͲ 
schizophrenia rare variants ȋTable ͳȌ had all been previously linked to autism, ʹͶͳ intellectual disability, and severe developmental disordersʹ͵,͵ʹ,͵͵. Our ʹͶʹ enrichment results matched some of the findings from a pathway analysis of ʹͶ͵ common risk variants in psychiatric disorders, which also implicated neuronal ʹͶͶ and chromatin gene setsʹͲ. (owever, unlike that study, we found no enrichment ʹͶͷ of rare variants in immune-related gene sets. ʹͶ͸  ʹͶ͹ We noticed that the ͳ,͹ͷͻ gene sets we tested were collectively enriched ʹͶͺ with LoF intolerant genes when compared to a random sampling of genes from ʹͶͻ the genome ȋSupplementary Figure ͸ and ͹Ȍ. For some of the gene sets ʹͷͲ associated with schizophrenia, this over-representation was quite substantial:  ʹͷͳ ͸͹% of the gene targets of FMRP and ͹Ͷ% of the genes associated with severe ʹͷʹ neurodevelopmental disorders are LoF intolerant. To better understand the ʹͷ͵ consequences of this overlap on our results, we extended the gene set ʹͷͶ enrichment methods ȋOnline MethodsȌ to condition on LoF intolerance and ʹͷͷ brain-expression for the ͵ͷ gene sets with FDR q < Ͳ.Ͳͷ in the previous analysis ʹͷ͸ ȋSupplementary Table ʹȌ. We first observed that ʹʹ of the ͵ͷ gene sets remained ʹͷ͹ significant even after conditioning on brain expression ȋSupplementary Tables ͵, ʹͷͺ Online MethodsȌ, suggesting they represent more specific biological processes ʹͷͻ involved in schizophrenia. (owever, only known autism risk genes ȋP = ʹ͸Ͳ Ͷ.Ͷ× ͳͲସȌ and neurodevelopmental disorder genes ȋP = ͵× ͳͲହȌ had an excess ʹ͸ͳ of rare coding variants above the enrichment already observed in LoF intolerant ʹ͸ʹ genes ȋSupplementary Table ͵Ȍ. Thus, in addition to biological pathways ʹ͸͵ implicated specifically in schizophrenia, at least a portion of the schizophrenia ʹ͸Ͷ risk conferred by rare variants of large effect is shared with childhood onset ʹ͸ͷ disorders of neurodevelopment. ʹ͸͸  ʹ͸͹ 
Schizophrenia patients with intellectual disability have a greater burden of rare ʹ͸ͺ 
damaging variants ʹ͸ͻ  ʹ͹Ͳ )n autism spectrum disorders, the observed excess of rare damaging ʹ͹ͳ variants has been shown to be greater in individuals with intellectual disability ʹ͹ʹ than those with normal levels of cognitive functionʹͺ. We observed a similar ʹ͹͵ phenomenon in schizophrenia cases carrying SETD1A LoF variantsͳͺ, so next ʹ͹Ͷ sought to explore whether this pattern is consistent in gene sets implicated in ʹ͹ͷ schizophrenia. We acquired relevant cognitive phenotype data for ʹ,ͻ͹ͳ of the ʹ͹͸ Ͷ,ͳ͵ͳ schizophrenia patients with whole-exome sequencing data ʹ͹͹ ȋSupplementary Figure ͺȌ. Of these individuals, ʹ͹ͻ were clinically diagnosed ʹ͹ͺ with intellectual disability in addition to fulfilling the full diagnostic criteria for ʹ͹ͻ schizophrenia ȋSCZ-)D subgroup, Online MethodsȌ. We also identified ͳ,ͳ͸ͷ ʹͺͲ individuals for whom we could rule out cognitive impairment ȋby excluding pre-ʹͺͳ morbid )Q < ͺͷ, fewer than ͳʹ years of schooling or lowest decile of composite ʹͺʹ cognitive measures, depending on available data, Online MethodsȌ. Finally, we ʹͺ͵ identified ͳ,ͷʹ͹ individuals who were not diagnosed with intellectual disability, ʹͺͶ but in whom some cognitive impairment could not be excluded.  ʹͺͷ  ʹͺ͸ When stratifying into these three groups ȋintellectual disability, no ʹͺ͹ intellectual disability but cognitive impairment not excluded, no cognitive ʹͺͺ impairmentȌ, we observed that the burden of rare damaging variants in LoF ʹͺͻ 
intolerant genes was significantly greater in the SCZ-)D subgroup than in the ʹͻͲ remaining schizophrenia cases ȋP = ʹ.͸ × ͳͲସ; OR ͳ.͵, ͳ.ͳʹ– ͳ.ͷͳ, ͻͷ% C)Ȍ or ʹͻͳ controls ȋP < ͷ × ͳͲ଻; OR ͳ.͸ͳ, ͳ.͵͹ – ͳ.ͺͻ, ͻͷ% C); Figure ͵Ȍ. )n the LoF ʹͻʹ intolerant gene set, Ͳ.ʹ͹ ȋͲ.ʹ – Ͳ.͵ͷ, ͻͷ% C)Ȍ extra singleton ȋdefined as having ʹͻ͵ an allele count of one in our data setȌ LoF variants were observed per exome in ʹͻͶ SCZ-)D cases compared to controls, while Ͳ.ͳͲ ȋͲ.Ͳ͸ͷ – Ͳ.ͳ͵, ͻͷ% C)Ȍ extra ʹͻͷ singleton LoF variants per exome were observed in the remaining schizophrenia ʹͻ͸ cases compared to controls ȋOnline MethodsȌ.  Furthermore, SCZ-)D individuals ʹͻ͹ had significant enrichment of rare LoF variants in developmental disorder genes ʹͻͺ compared to the other cases ȋP = ͻ × ͳͲସ; OR ʹ.͵͸, ͳ.Ͷͳ– ͵.ͻʹ, ͻͷ% C)Ȍ or to ʹͻͻ controls ȋP = ͻ.ͷ × ͳͲ଺; OR ͵.Ͷ͵, ʹ.Ͳͳ– ͷ.ͺ͸, ͻͷ% C); Figure ͶȌ. Compared to ͵ͲͲ controls, the SCZ-)D individuals carried Ͳ.ͲͶͷ ȋͲ.Ͳ͵ – Ͳ.Ͳ͸, ͻͷ% C)Ȍ extra ͵Ͳͳ singleton LoF variants in developmental disorder genes per exome, suggesting ͵Ͳʹ that around Ͷ% of these cases had a LoF variant that is relevant to their clinical ͵Ͳ͵ presentation. No enrichment in neurodevelopmental disorder genes was ͵ͲͶ observed in schizophrenia patients without intellectual disability, suggesting ͵Ͳͷ that these genes were relevant only for that subset of schizophrenia patients ͵Ͳ͸ ȋFigure Ͷ, Supplementary Table ͶȌ. Notably, even after excluding known ͵Ͳ͹ developmental disorder genes from the set of LoF intolerant genes, we still ͵Ͳͺ observed an enrichment of rare variants in SCZ-)D patients compared to the ͵Ͳͻ remaining cases ȋP = ͳ × ͳͲଷ; ͳ.ʹ͸, ͳ.Ͳͺ – ͳ.Ͷ͹, ͻͷ% C)Ȍ or to controls ȋP ͵ͳͲ < ͷ × ͳͲ଻; OR ͳ.ͷͶ, ͳ.͵ͳ– ͳ.ͺͳ, ͻͷ% C); Supplementary Figure ͻȌ. Rare variation ͵ͳͳ in these genes contributes more to disease risk in the subset of patients with ͵ͳʹ both schizophrenia and intellectual disability.  ͵ͳ͵  ͵ͳͶ 
Rare variants confer risk for schizophrenia in individuals without intellectual ͵ͳͷ 
disability ͵ͳ͸  ͵ͳ͹  While rare damaging variants in LoF intolerant genes were most enriched ͵ͳͺ in the subset of schizophrenia patients with intellectual disability, we still ͵ͳͻ observed a weaker but significant enrichment in individuals with schizophrenia ͵ʹͲ for whom we could confirm do not have intellectual disability ȋP = ͷ.ͷ × ͳͲସ; ͵ʹͳ ͳ.ͳ͸, ͳ.Ͳͷ – ͳ.ʹ͹, ͻͷ% C); Figure ͵Ȍ. Therefore, rare risk variants for ͵ʹʹ schizophrenia follow the pattern previously described in autism: concentrated in ͵ʹ͵ individuals with intellectual disability, but not exclusive to that group. To ͵ʹͶ produce a more accurate estimate of the effect of damaging rare variants on ͵ʹͷ schizophrenia conditional on their effects on overall cognition, we recalculated ͵ʹ͸ the enrichment of rare variants in LoF intolerant genes in a subset of ʹ,ͳ͸ͳ ͵ʹ͹ schizophrenia cases and ʹ,͵ͻͺ controls for which data on years of education was ͵ʹͺ available and for whom intellectual disability could be excluded ȋSupplementary ͵ʹͻ Figure ͺȌ. After controlling for differences in educational attainment ȋOnline ͵͵Ͳ MethodsȌ, individuals with schizophrenia have a ͳ.ʹ͸-fold excess of rare variants ͵͵ͳ in LoF intolerant genes ȋP = ʹ × ͳͲ଺; ͳ.ͳͶ – ͳ.͵ͺ, ͻͷ% C)Ȍ. This increase in our ͵͵ʹ observed odds ratio is consistent with previous accounts that rare damaging ͵͵͵ variants also affect educational attainment in controls͵ͻ, thus biasing our ͵͵Ͷ unconditional estimate. ͵͵ͷ 
Discussion ͵͵͸   ͵͵͹ 
Our integrated analysis of thousands of whole-exome sequences ͵͵ͺ demonstrates that rare damaging variants increase risk of schizophrenia both ͵͵ͻ with and without co-morbid intellectual disability. While the identification of ͵ͶͲ individual genes remains difficult at current samples sizes, we show that the ͵Ͷͳ burden of damaging de novo mutations, rare SNVs and CNVs in schizophrenia is ͵Ͷʹ not scattered across the genome but is primarily concentrated in ͵,Ͷͺͺ genes ͵Ͷ͵ intolerant of loss-of-function variants. This observation is shared with autism, ͵ͶͶ intellectual disability, and severe neurodevelopmental disorders͵ʹ,ͶͲ. We ͵Ͷͷ recapitulate enrichment in previously published gene sets, including ͵Ͷ͸ transmission at glutamatergic synapses and translational regulation by FMRP, ͵Ͷ͹ and implicate other gene sets previously linked to autism, intellectual disability, ͵Ͷͺ and severe developmental disorders. (owever, we find that all of these gene sets ͵Ͷͻ share a large number of underlying genes, and are especially enriched with the ͵ͷͲ ͵,Ͷͺͺ genes intolerant of LoF variants. These overlaps among gene sets ͵ͷͳ originating from very different analyses, as well as the subtleties of how they are ͵ͷʹ defined, suggest caution in interpreting biological explanations from observed ͵ͷ͵ enrichments. ͵ͷͶ  ͵ͷͷ We jointly analyzed the case-control SNV data with information on ͵ͷ͸ cognitive function for ʹ,ͻ͹ͳ patients, and find that LoF variants disrupting genes ͵ͷ͹ associated with severe developmental disorders are disproportionately found in ͵ͷͺ individuals with schizophrenia with co-morbid intellectual disability, with Ͷ% of ͵ͷͻ these cases having a single LoF variant that is relevant to their clinical ͵͸Ͳ presentation. Even after excluding variants in known developmental disorder ͵͸ͳ genes, rare variants contribute a greater degree to schizophrenia risk in the SCZ-͵͸ʹ )D subgroup of patients than the remaining schizophrenia population. These ͵͸͵ results show that some of these genetic perturbations have clear manifestations ͵͸Ͷ in childhood, and that rare risk variants in schizophrenia are particularly ͵͸ͷ associated with co-morbid intellectual disability. Our observations are consistent ͵͸͸ with results in autism in which rare risk variants are associated with intellectual ͵͸͹ disabilityʹʹ,ʹ͵,ʹͺ.  Notably, a weaker but still significant rare variant burden was ͵͸ͺ observed in schizophrenia patients without cognitive impairment, and this signal ͵͸ͻ persists even after controlling for educational attainment. Together, these results ͵͹Ͳ demonstrate that rare variants have different contributions to schizophrenia risk ͵͹ͳ depending on the degree of cognitive impairment. )mportantly, they do not ͵͹ʹ simply confer risk for a small subset of patients but contribute to disease ͵͹͵ pathogenesis more broadly.   ͵͹Ͷ  ͵͹ͷ Our study supports the observation that genetic risk factors for ͵͹͸ psychiatric and neurodevelopmental disorders do not follow clear diagnostic ͵͹͹ boundaries. Coding variants disrupting the same genes, and quite possibly, the ͵͹ͺ same biological processes, increase risk for a range of phenotypic manifestation. ͵͹ͻ This clinically variable presentation is reminiscent of LoF variants in SETD1A ͵ͺͲ and ͳͳ large copy number variant syndromes, previously shown to confer risk ͵ͺͳ for schizophrenia in addition to other prominent developmental defectsͳ͸,ͳͺ. )t is ͵ͺʹ possible that these genes contain an allelic series of variants conferring ͵ͺ͵ gradations of risk. A recent schizophrenia GWAS meta-analysis demonstrated ͵ͺͶ that the common variant association signal was similarly enriched in LoF ͵ͺͷ intolerant genesͶͳ, suggesting that schizophrenia risk genes may be perturbed by ͵ͺ͸ 
common variants of subtle effects and disrupted by rare variants of high ͵ͺ͹ penetrance in the population. This possibility is also supported by the overlap in ͵ͺͺ at least some of the pathways affected by both rare and common variation, such ͵ͺͻ as chromatin remodeling. (owever, the most common deletion in the ʹʹqͳͳ.ʹ ͵ͻͲ locus and a recurrent two base deletion in SETD1A are associated with both ͵ͻͳ schizophrenia and more severe neurodevelopmental disorders, suggesting the ͵ͻʹ same variants can also confer risk for a range of clinical featuresͳͺ,Ͷʹ,Ͷ͵. ͵ͻ͵ Ultimately, it may prove difficult to clearly partition patients genetically into ͵ͻͶ subtypes with similar clinical features, especially if genes and variants ͵ͻͷ previously thought to cause well-characterized Mendelian disorders can have ͵ͻ͸ such varied outcomes. This pattern is consistent with the hypothesis that LoF ͵ͻ͹ variants in genes under genic constraint result in a spectrum of ͵ͻͺ neurodevelopmental outcomes with the burden of mutations highest in ͵ͻͻ intellectual disability and least in schizophrenia, corresponding to a gradient of ͶͲͲ neurodevelopmental pathology indexed by the degree of cognitive impairment, ͶͲͳ age of onset, and severityͶ.  ͶͲʹ  ͶͲ͵ Despite the complex nature of genetic contributions to risk of ͶͲͶ schizophrenia, it is notable that across study design ȋtrio or case-controlȌ and ͶͲͷ variant class ȋSNVs or CNVsȌ, risk loci of large effect are concentrated in a small ͶͲ͸ subset of genes. Previous rare variant analyses in other neurodevelopmental ͶͲ͹ disorders, such as autism, have successfully integrated information across de ͶͲͺ 
novo SNVs and CNVs to identify novel risk lociʹ͵. As sample sizes increase, meta-ͶͲͻ analyses leveraging the shared genetic risk across study designs and variant ͶͳͲ types, including those we did not consider here, such as classical recessive Ͷͳͳ inheritance, will be similarly well powered to identify additional risk genes in Ͷͳʹ schizophrenia. Ͷͳ͵  ͶͳͶ 
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Figure captions ͷͺͻ  ͷͻͲ 
Figure 1: Analysis workflow. Data sets are shown in blue, statistical methods ͷͻͳ and analysis steps are shown in green, and results ȋfigures and tablesȌ from the ͷͻʹ analysis are shown in orange. A: Enrichment analyses in ͳ,͹͸͸ gene sets using ͷͻ͵ the entire rare variant data set. B: Enrichment analyses in LoF intolerant and ͷͻͶ developmental disorder genes in the subset of cases with information on ͷͻͷ cognitive function. )D: intellectual disability; SCZ: schizophrenia; SCZ-)D: ͷͻ͸ schizophrenia patients with intellectual disability.  ͷͻ͹ 
Figure 2: Enrichment of schizophrenia rare variants in genes intolerant of loss-ͷͻͺ of-function variants. A: Schizophrenia cases compared to controls for rare SNVs ͷͻͻ and indels; B: Rates of de novo mutations in schizophrenia probands compared ͸ͲͲ to control probands; C: Case-control CNVs. P-values shown were from the test of ͸Ͳͳ LoF enrichment in A, LoF enrichment in B, and all CNVs enrichment in C. Error ͸Ͳʹ bars represent the ͻͷ% C) of the point estimate. LoF intolerant: ͵,ͶͶͺ genes with ͸Ͳ͵ near-complete depletion of truncating variants in the ExAC database; Rest: the ͸ͲͶ remaining genes in the genome with pL) < Ͳ.ͻ; Damaging missense: missense ͸Ͳͷ variants with CADD phred > ͳͷ. Asterisk: P < ͳ x ͳͲ-͵. ͸Ͳ͸  ͸Ͳ͹ 
Figure 3: Enrichment of rare loss-of-function variants in LoF intolerant genes in ͸Ͳͺ schizophrenia cases stratified by information on cognitive function compared to ͸Ͳͻ controls. The P-values shown were calculated using the variant threshold ͸ͳͲ method comparing LoF burden between the corresponding cases and controls. ͸ͳͳ Error bars represent the ͻͷ% C) of the point estimate. Damaging missense: ͸ͳʹ missense variants with CADD phred > ͳͷ. ͸ͳ͵  ͸ͳͶ 
Figure 4: Enrichment of rare loss-of-function variants in known severe ͸ͳͷ developmental disorder genes in schizophrenia cases stratified by information ͸ͳ͸ on cognitive function compared to controls. The P-values shown were calculated ͸ͳ͹ using the variant threshold method comparing LoF burden between the ͸ͳͺ corresponding cases and controls. Error bars represent the ͻͷ% C) of the point ͸ͳͻ estimate. Damaging missense: missense variants with CADD phred > ͳͷ. ͸ʹͲ  ͸ʹͳ 
Table 1: Gene sets enriched for rare coding variants conferring risk for schizophrenia at FDR < ͳ%. The effect sizes and corresponding ͸ʹʹ 











ExAC LoF intolerant 
genes 
(pLI > 0.9) 
3488 1.24  1.16-1.31 < 5.0 x 10
-7
 1.36  1.1-1.68 0.0067 1.21  1.15-1.28 0.00026 < 3.60 x 10
-10
 4.30 x 10
-7
Dominant, diagnostic 
DDG2P genes, in which 
LoF variants result in 
developmental disorders 
with brain abnormalities 
156 1.42  1.07-1.88 0.011 4.18  2.21-8.03 0.00073 1.92  1.54-2.39 0.0016 2.30 x 10
-6
 0.00067 
Sanders et al. autism risk 
genes (FDR < 10%) 
66 1.28  0.97-1.69 0.0095 3.96  1.65-9.94 0.019 2.21  1.75-2.79 0.00033 9.50 x 10
-6
 0.0017 
Darnell et al. targets of 
FMRP 
790 1.24  1.13-1.36 8.5 x 10
-6
 1.31 0.83-2.09 0.17 1.32  1.2-1.47 0.0032 9.30 x 10
-7
 0.00038 
Cotney et al. CHD8-
targeted promoters (hNSC 
and human brain tissue) 
2920 1.09  1.02-1.16 0.0008 1.77 1.36-2.31 0.00025 1.11  1.05-1.18 0.027 1.10 x 10
-6
 0.00038 
G2CDB: mouse cortex 
post-synaptic density 
consensus 
1527 1.20  1.11-1.3 2.5 x 10
-6




CLIP targets of RBFOX 
967 1.21  1.11-1.33 4.8 x 10
-5
 1.84  1.21-2.8 0.0085 1.07  0.98-1.17 0.2 1.30 x 10
-5
 0.002 
NMDAR network (defined 
in Purcell et al.)






519 1.29  1.13-1.49 0.00018 2.26  1.32-3.94 0.0099 1.12  0.99-1.28 0.18 4.20 x 10
-5
 0.0046 
Supplementary Table captions ͸ʹ͹ ͸ʹͺ 
Supplementary Table 1: Full results from enrichment analyses of ͳ,͹͸͸ gene ͸ʹͻ sets. The P-values from enrichment tests of each variant type ȋcase-control SNVs, ͸͵Ͳ DNM, and case-control CNVsȌ are shown for each gene set, along with the ͸͵ͳ Fisherǯs combined P-value ȋPmetaȌ and the FDR-corrected Q-value ȋQmetaȌ. Ngenes: ͸͵ʹ number of genes in the gene set; SNV: single nucleotide variants from whole-͸͵͵ exome data; DNM: de novo mutations. ͸͵Ͷ ͸͵ͷ 
Supplementary Table 2: Gene sets enriched for rare coding variants conferring ͸͵͸ risk for schizophrenia at FDR < ͷ%. The effect sizes and corresponding P-values ͸͵͹ from enrichment tests of each variant type ȋcase-control SNVs, DNM, and case-͸͵ͺ control CNVsȌ are shown for each gene set, along with the Fisherǯs combined P-͸͵ͻ value ȋPmetaȌ and the FDR-corrected Q-value ȋQmetaȌ. Ngenes: number of genes in ͸ͶͲ the gene set; Est: effect size estimate and its lower and upper bound assuming a ͸Ͷͳ ͻͷ% C); SNV: single nucleotide variants from whole-exome data; DNM: de novo ͸Ͷʹ mutations. ͸Ͷ͵ ͸ͶͶ 
Supplementary Table 3: Results from enrichment analyses of FDR < ͷ% gene ͸Ͷͷ sets, conditional on brain-expressed and ExAC LoF intolerant genes.  We restrict ͸Ͷ͸ enrichment analyses to genes that reside in two different background gene sets, ͸Ͷ͹ one defined on brain-enriched expression in GTeX, and the second on genic ͸Ͷͺ constraint ȋExAC LoF intolerant genesȌ, and determined if gene sets with FDR < ͸Ͷͻ ͷ% in the meta-analysis still had significance above the specific background. The ͸ͷͲ 
P-values from enrichment tests of each variant type ȋcase-control SNVs, DNM, ͸ͷͳ and case-control CNVsȌ are shown for each gene set, along with the Fisherǯs ͸ͷʹ combined P-value ȋPmetaȌ. SNV: single nucleotide variants from whole-exome ͸ͷ͵ data; DNM: de novo mutations ͸ͷͶ  ͸ͷͷ 
Supplementary Table 4: Results from enrichment analyses of rare loss-of-͸ͷ͸ function variants in LoF intolerant genes and developmental disorder genes ͸ͷ͹ comparing schizophrenia cases stratified by information on cognitive function ͸ͷͺ and matched controls. Each comparison is defined in the Table, and the P-values ͸ͷͻ shown were calculated using the variant threshold method comparing LoF ͸͸Ͳ burden between the corresponding case and baseline samples. Ncase: number of ͸͸ͳ case samples; Ncomparison: number of comparison samples; Estimates: effect size ͸͸ʹ estimate and its lower and upper bound assuming a ͻͷ% C). ͸͸͵ 
Online Methods ͸͸Ͷ 
Sample collections  ͸͸ͷ  ͸͸͸ The ascertainment, data production, and quality control of the ͸͸͹ schizophrenia case-control whole-exome sequencing data set had been ͸͸ͺ described in detail in an earlier publicationͳͺ. Briefly, the data set was composed ͸͸ͻ of schizophrenia cases recruited as part of eight collections in the UKͳͲK ͸͹Ͳ sequencing project, and matched population controls from non-psychiatric arms ͸͹ͳ of the UKͳͲK project, healthy blood donors from the )NTERVAL project, and five ͸͹ʹ 
Finnish population studies. The UKͳͲK data set was combined and analyzed ͸͹͵ with published data from a Swedish schizophrenia case-control study͵ͷ. The data ͸͹Ͷ production, quality control, and analysis of the case-control CNV data set was ͸͹ͷ described in an earlier publicationʹͻ. The schizophrenia cases were recruited as ͸͹͸ part of the CLOZUK and CardiffCOGS studies, which consisted of both ͸͹͹ schizophrenia individuals taking the antipsychotic clozapine and a general ͸͹ͺ sample of cases from the UK. Matched controls were selected from four publicly ͸͹ͻ available non-psychiatric data sets.  All samples were genotyped using )llumina ͸ͺͲ arrays, and processed and called under the same protocol. Sanger-validated de ͸ͺͳ 
novo mutations identified through whole exome-sequencing in seven published ͸ͺʹ studies of schizophrenia parent-proband trios were aggregated and re-annotated ͸ͺ͵ for enrichment analysesͳ͵,ͶͶ–Ͷͻ. A full description of each trio study, including ͸ͺͶ sequencing and capture technology and sample recruitment was previously ͸ͺͷ describedͳͺ.  ͸ͺ͸ 
Sample and variant quality control ͸ͺ͹  ͸ͺͺ We jointly called each case data set with its nationality-matched controls, ͸ͺͻ and excluded samples based on contamination, coverage, non-European ͸ͻͲ ancestry, and excess relatednessͳͺ. A number of empirically derived filters were ͸ͻͳ applied at the variant and genotype level, including filters on GATK VQSR, ͸ͻʹ genotype quality, read depth, allele balance, missingness, and (ardy-Weinberg ͸ͻ͵ disequilibriumͳͺ. After variant filtering, the per-sample transition-to-͸ͻͶ transversion ratio was ~͵.ʹ across the entire data set, as expected for ͸ͻͷ populations of European ancestryͷͲ. For the case-control CNV analysis, we ͸ͻ͸ similarly excluded samples based on excess relatedness, and only CNVs ͸ͻ͹ supported by more than ͳͲ probes and greater than ͳͲ kilobases in size were ͸ͻͺ retained to ensure high quality calls. All de novo mutations in our study had been ͸ͻͻ validated using Sanger sequencing.  ͹ͲͲ  ͹Ͳͳ We used the Ensembl Variant Effect Predictor ȋVEPȌ version ͹ͷ to ͹Ͳʹ annotate all variants ȋSNVs and CNVsȌ according to Gencode v.ͳͻ coding ͹Ͳ͵ transcripts. We defined frameshift, stop gained, splice acceptor, and donor ͹ͲͶ variants as loss-of-function ȋLoFȌ, and missense or initiator codon variants with ͹Ͳͷ the recommended CADD Phred score cut-off of greater than ͳͷ as damaging ͹Ͳ͸ missenseͷͳ. A gene was annotated as disrupted by a deletion if part of its coding ͹Ͳ͹ sequence overlapped the copy number event. We more conservatively defined ͹Ͳͺ genes as duplicated only if the entire canonical transcript of the gene overlapped ͹Ͳͻ with the duplication event.  ͹ͳͲ  ͹ͳͳ Statistical tests of the case-control exome data used case-control ͹ͳʹ permutations within each population ȋUK, Finnish, SwedishȌ to generate ͹ͳ͵ empirical P-values to test hypotheses. No genome-wide inflation was observed in ͹ͳͶ burden tests of individual genesͳͺ. )n the curated set of de novo mutations, we ͹ͳͷ observed the expected exome-wide number of synonymous mutations given ͹ͳ͸ gene mutation rates from previously validated modelsʹͶ, suggesting variant ͹ͳ͹ calling was generally unbiased across Gencode v.ͳͻ coding genes. Lastly, the ͹ͳͺ case-control CNV data set had been previously analyzed for burden of CNVs ͹ͳͻ affecting individual genes, and enrichment analyses in targeted gene sets͹,ʹͻ.  ͹ʹͲ 
Rare variant gene set enrichment analyses ͹ʹͳ 
Case-control enrichment burden tests For the case-control SNV data set, we ͹ʹʹ performed permutation-based gene set enrichment tests using an extension of ͹ʹ͵ the variant threshold method͵Ͳ. This method assumed that variants with a MAF ͹ʹͶ below an unknown threshold  were more likely to be damaging than variants ͹ʹͷ with a MAF above , and this threshold was allowed to differ for every gene or ͹ʹ͸ pathway tested. To consider different possible values for threshold , a gene or ͹ʹ͹ gene set test statistic ݐሺሻ was calculated for every allowable , and the ͹ʹͺ maximum test-statistic, or ݐ୫, was selected. The statistical significance of ݐ୫ ͹ʹͻ was evaluated by permuting phenotypic labels, and calculating ݐ୫ from the ͹͵Ͳ permuted data such that different values of  could be selected following each ͹͵ͳ permutation. )n Price et al., ݐሺሻ was defined as the -score calculated from ͹͵ʹ regressing the phenotype on the sum of the allele counts of variants in a gene ͹͵͵ with MAF  . We extended this method to test for enrichment in gene sets by ͹͵Ͷ regressing schizophrenia status on the total number of damaging alleles in the ͹͵ͷ gene set of interest with MAF   ȋ,Ȍ while correcting for the total number of ͹͵͸ damaging alleles genome-wide with MAF   ȋ,Ȍ. , controlled for ͹͵͹ exome-wide differences between schizophrenia cases and controls, ensuring any ͹͵ͺ significant gene set result was significant beyond baseline differences. ݐሺሻ was ͹͵ͻ defined as the ݐ-statistic testing if the regression coefficient of , deviated ͹ͶͲ from Ͳ. We then calculated ݐሺሻ for all observed thresholds below a minor allele ͹Ͷͳ frequency of Ͳ.ͳ%, and selected the maximum value for the ݐ୫ based on the ͹Ͷʹ observed data. To calculate a null distribution for ݐ୫, we performed two ͹Ͷ͵ million case-control permutations within each population ȋUK, Finnish, and ͹ͶͶ SwedishȌ to control for batch and ancestry, and calculated ݐ୫ for each ͹Ͷͷ permuted sample while allowing  to vary. The -value for each gene set was ͹Ͷ͸ calculated as the fraction of the two million permuted samples that had a greater ͹Ͷ͹ ݐ୫ than what was observed in the unpermuted data. The odds ratio and ͻͷ% ͹Ͷͺ confidence interval of each gene set was calculated using a logistic regression ͹Ͷͻ model, regressing schizophrenia status on  while controlling for total number ͹ͷͲ of variants genome-wide ȋȌ and population ȋUK, Finnish, and SwedishȌ. ͹ͷͳ Unlike gene set -values which were calculated using permutation across ͹ͷʹ multiple frequency thresholds, the odds ratios an d ͻͷ% C) were calculated using ͹ͷ͵ only variants observed once in our data set ȋallele count of ͳȌ to ensure they ͹ͷͶ were comparable between tested gene sets. ͹ͷͷ 
CNV logistic regression We adapted a logistic regression framework described in ͹ͷ͸ Raychaudhuri et al. and implemented in PL)NK to compare the case-control ͹ͷ͹ differences in the rate of CNVs overlapping a specific gene set while correcting ͹ͷͺ for differences in CNV size and total genes disrupted͹,ͳͻ,͵ͳ. We first restricted our ͹ͷͻ analyses to coding deletions and duplications, and tested for enrichment using ͹͸Ͳ the following model:  ͹͸ͳ log  ,ଵ,  ଴ + ଵݏ + ଶ୪୪ + ଷ୬ + , ͹͸ʹ where for individual i, pi is the probability they have schizophrenia i, si is the ͹͸͵ total length of CNVs, gall is the total number of genes overlapping CNVs, and gin is ͹͸Ͷ the number of genes within the gene set of interest overlapping CNVs. )t has been ͹͸ͷ shown that ଵ and ଶ sufficiently controlled for the genome-wide differences in ͹͸͸ 
the rate and size of CNVs between cases and control, while ଷ captured the true ͹͸͹ gene set enrichment above this background rate͹,ͳͻ,͵ͳ. For each gene set, we ͹͸ͺ reported the one-sided P-value, odds ratio, and ͻͷ% confidence interval of ଷ.  ͹͸ͻ 
Weighted permutation-based sampling of de novo mutations For each variant ͹͹Ͳ class of interest, we first determined the total number of de novo mutations ͹͹ͳ observed in the ͳ,Ͳ͹͹ schizophrenia trios. We then generated ʹ million random ͹͹ʹ samples with the same number of de novo mutations, weighting the probability ͹͹͵ of observing a mutation in a gene by its estimated mutation rate. The baseline ͹͹Ͷ gene-specific mutation rates were obtained using the method described in ͹͹ͷ Samocha et al. and adapted to produce LoF and damaging missense rates for ͹͹͸ each Gencode v.ͳͻ gene. These mutation rates adjusted for both sequence ͹͹͹ context and gene length, and were successfully applied in the primary analyses ͹͹ͺ of large-scale exome sequencing of autism and severe developmental disorders ͹͹ͻ with replicable resultsʹ͵,͵ʹ,ͶͲ. For each gene set, one-sided enrichment P-values ͹ͺͲ were calculated as the fraction of two million random samples that had a greater ͹ͺͳ or equal number of de novo mutations in the gene set of interest than what is ͹ͺʹ observed in the ͳ,Ͳ͹͹ trios. The effect size of the enrichment was calculated as ͹ͺ͵ the ratio between the number of observed mutations in the gene set of interest ͹ͺͶ and the average number of mutations in the gene set across the two million ͹ͺͷ random samples. We adapted a method in Fromer et al. to calculate ͻͷ% credible ͹ͺ͸ intervals for the enrichment statisticͳ͵. We first generated a list of one thousand ͹ͺ͹ evenly spaced values between Ͳ and ten times the point estimate of the ͹ͺͺ enrichment. For each value, the mutation rates of genes in the gene set of ͹ͺͻ interest were multiplied by that amount, and ͷͲ,ͲͲͲ random samples of de novo ͹ͻͲ mutations were generated using these weighted rates. The probability of ͹ͻͳ observing the number of mutations in the gene set of interest given each effect ͹ͻʹ size multiplier was calculated as the fraction of samples in which the number of ͹ͻ͵ mutations in the gene set is the same as the observed number in the ͳ,Ͳ͹͹ trios. ͹ͻͶ We normalized the probabilities across the ͳ,ͲͲͲ values to generate a posterior ͹ͻͷ distribution of the effect size, and calculated the ͻͷ% credible interval using this ͹ͻ͸ empirical distribution.  ͹ͻ͹ ͹ͻͺ 
Combined joint analysis Gene set P-values calculated using the case-control SNV, ͹ͻͻ case-control CNV, and de novo data were meta-analyzed using Fisherǯs combined ͺͲͲ probability method with df = ͸ to provide a single test statistic for each gene set. ͺͲͳ We corrected for the number of gene sets tested in the discovery analysis ȋn = ͺͲʹ ͳ,͹͹͸Ȍ by controlling the false discovery rate ȋFDRȌ using the Benjamini-ͺͲ͵ (ochberg approach, and reported only results with a q-value of less than ͷ%. ͺͲͶ ͺͲͷ 
Description of gene sets ͺͲ͸  ͺͲ͹ The full list of tested gene sets is found in Supplementary Table ͳ, and a ͺͲͺ detailed description is provided in the Supplementary Note. Briefly, we tested all ͺͲͻ gene sets with more than ͳͲͲ genes from five public pathway databases. We ͺͳͲ additionally tested additional gene sets selected based on biological hypotheses ͺͳͳ about schizophrenia risk, and genome-wide screens investigating rare variants ͺͳʹ in intellectual disability, autism spectrum disorders, and other ͺͳ͵ neurodevelopmental disorders. All gene identifiers were mapped to the ͺͳͶ 
GENCODE v.ͳͻ release, and all non-coding genes were excluded. A total of ͳ,͹͸͸ ͺͳͷ gene sets were included in our analysis. ͺͳ͸ 
Selection of allele frequency thresholds and consequence severity  ͺͳ͹  ͺͳͺ For the case-control whole-exome data, we applied an extension of the ͺͳͻ variant threshold model ȋdescribed aboveȌ. With this method, we tested ͺʹͲ damaging variants at a number of frequency thresholds without specifying an a ͺʹͳ 
priori MAF cut-off. All thresholds below a MAF of Ͳ.ͳ% observed in our data ͺʹʹ were tested, and we assessed statistical significance by permutation testing. For ͺʹ͵ all the whole-exome data ȋcase-control and trio dataȌ, we restricted our analyses ͺʹͶ to loss-of-function variants. These variants have a clear and severe predicted ͺʹͷ functional consequence in that they putatively cause a single-copy loss of a gene. ͺʹ͸ Furthermore, this class of variants had been demonstrated to have the strongest ͺʹ͹ genome-wide enrichment between cases and controls across ͺʹͺ neurodevelopmental and psychiatric disordersͳͺ,͵ʹ,ͶͲ. When selecting MAF cut-ͺʹͻ offs for case-control CNVs, we found that while the bulk of the test statistics were ͺ͵Ͳ not inflated, the tail of gene set P-values were dramatically inflated even when ͺ͵ͳ testing for enrichment in the random gene sets ȋSupplementary Figure ͳȌ. This ͺ͵ʹ inflation in the tail of the Q-Q plot was driven in part by very large ȋoverlapping ͺ͵͵ more than ͳͲ genesȌ, more common ȋMAF between Ͳ.ͳ% and ͳ%Ȍ CNVs ͺ͵Ͷ observed mainly in cases or controls. Some of these, such as the known ͺ͵ͷ syndromic CNVs, likely harbored true risk genes. (owever, because these CNVs ͺ͵͸ were highly recurrent in cases and depleted in controls, and disrupted a large ͺ͵͹ number of genes, any gene set that included even a single gene within these ͺ͵ͺ CNVs would appear to be significant, even after controlling for total CNV length ͺ͵ͻ and genes overlapped. To ensure our model was well calibrated and its P-values ͺͶͲ followed a null distribution for random gene sets, we explored different ͺͶͳ frequency and size thresholds, and conservatively restricted our analysis to copy ͺͶʹ number events overlapping less than seven genes ȋexcluding the largest ͳͲ% of ͺͶ͵ CNVsȌ with MAF < Ͳ.ͳ% ȋSupplementary Figure ͳȌ. Our main conclusions ͺͶͶ remained unchanged even if we selected a more stringent ȋexcluding the largest ͺͶͷ ͳͷ% of CNVsȌ or less stringent ȋexcluding the largest ͷ% of CNVsȌ size threshold. ͺͶ͸  ͺͶ͹ 
Robustness of enrichment analyses ͺͶͺ ͺͶͻ We uniformly sampled genes from the genome ȋas defined by Gencode ͺͷͲ v.ͳͻȌ to generate random gene sets with the same size distribution as the ͳ,͹͹͸ ͺͷͳ gene sets in our discovery analysis. For each random set, we calculated gene set ͺͷʹ 
P-values for the case-control SNV data, case-control CNV data, and de novo data ͺͷ͵ using the appropriate method and frequency cut-offs across all variant classes. A ͺͷͶ Q-Q plot was generated using P-values from enrichment tests of each data set ͺͷͷ and variant type. Reassuringly, we observed null distributions in all such Q-Q ͺͷ͸ plots ȋSupplementary Figure ͵Ȍ. ͺͷ͹ ͺͷͺ 
Comparison of de novo enrichment with broader neurodevelopmental ͺͷͻ 
disorders ͺ͸Ͳ ͺ͸ͳ 
We aggregated and re-annotated de novo mutations from four studies: ͺ͸ʹ ͳ,ͳͳ͵ severe DD probandsͶͲ, Ͷ,Ͳ͵ͺ ASD probandsʹ͵,͵ʹ, and ʹ,ͳ͵Ͷ control ͺ͸͵ probandsʹͺ,͵ʹ. We used the Poisson exact test to calculate differences in de novo ͺ͸Ͷ rates in constrained genes between schizophrenia, ASD, and DD and controls. ͺ͸ͷ Counts in each functional class ȋsynonymous, missense, damaging missense, and ͺ͸͸ LoFȌ were tested separately, and the one-sided P-value, rate ratio, and ͻͷ% C) of ͺ͸͹ each comparison were reported and plotted in Figure ʹ, Supplementary Figure Ͷ ͺ͸ͺ and ͷ.  ͺ͸ͻ  ͺ͹Ͳ 
Conditional analyses ͺ͹ͳ  ͺ͹ʹ )n each of the three methods we used for gene set enrichment, we ͺ͹͵ restricted all variants analyzed to those that reside in the background gene list, ͺ͹Ͷ and tested for an excess of rare variants in genes shared between the gene set of ͺ͹ͷ interest ȋKȌ and the background list ȋBȌ. Brain-enriched genes from GTEx, and ͺ͹͸ the ExAC LoF intolerant genes ȋpL) > Ͳ.ͻȌ were used as backgrounds ȋsee aboveȌ. ͺ͹͹ For the case-control SNV data, we modified the variant threshold method to ͺ͹ͺ regress schizophrenia status on the total number of damaging alleles in genes ͺ͹ͻ present in both the gene set of interest and the background gene set ȋ ∩ Ȍ, ͺͺͲ while correcting for the total number of damaging alleles in the set of all ͺͺͳ background genes ȋȌ. The logistic regression model for the case-control CNV ͺͺʹ data was modified to:  ͺͺ͵ log  ,ଵ,  ଴ + ଵݏ + ଶ + ଷ ∩  + , ͺͺͶ where gB is the total number of background genes overlapping a CNV, and  ∩  is ͺͺͷ the number of genes in the intersection of the gene set of interest and the ͺͺ͸ background list overlapping a CNV. Finally, we determined the total number of ͺͺ͹ 
de novo mutations within the background gene list observed in the ͳ,Ͳ͹͹ ͺͺͺ schizophrenia trios, and generated ʹ million random samples with the same ͺͺͻ number of de novo mutations. For each gene set, one-sided enrichment P-values ͺͻͲ were calculated as the fraction of two million random samples that had a greater ͺͻͳ or equal number of de novo mutations in genes in  ∩   than what is observed in ͺͻʹ the ͳ,Ͳ͹͹ trios. Gene set P-values were combined using Fisherǯs method. We ͺͻ͵ restricted our conditional enrichment analysis to gene sets with q-value < ͷ% in ͺͻͶ the discovery analysis, and adjusted for multiple testing using Bonferroni ͺͻͷ correction ȋP  Ͳ.ͲͲͲ͹ͳ, or Ͳ.Ͳͷ/͸͹ tests; see Supplementary Table ͵Ȍ. ͺͻ͸ ͺͻ͹ 
Rare variants and cognition in schizophrenia ͺͻͺ  Within the UKͳͲK study, ͻ͹ individuals from the MU)R collection were ͺͻͻ given discharge diagnoses of mild learning disability and schizophrenia ȋ)CD-ͺ ͻͲͲ and -ͻȌ. The recruitment guidelines of the MU)R collection were described in ͻͲͳ detail in a previous publicationͷʹ. )n brief, evidence of remedial education was a ͻͲʹ prerequisite to inclusion, and individuals with pre-morbid )Qs below ͷͲ or above ͻͲ͵ ͹Ͳ, severe learning disabilities, or were unable to give consent were excluded. ͻͲͶ The Schizophrenia and Affective Disorders Schedule-Lifetime version ȋSADS-LȌ ͻͲͷ in people with mild learning disability, PANSS, RDC, and DSM-)))-R, and St. Louis ͻͲ͸ Criterion were applied to all individuals to ensure that any diagnosis of ͻͲ͹ 
schizophrenia was robust. Using the clinical information provided alongside the ͻͲͺ Swedish and Finnish case-control data sets, we identified additional ͳͺʹ ͻͲͻ schizophrenia individuals who were similarly diagnosed with intellectual ͻͳͲ disability, for a total of ʹ͹ͻ individuals. ͻͳͳ Cognitive testing and educational attainment data available for a subset of ͻͳʹ samples were used identify schizophrenia individuals without cognitive ͻͳ͵ impairment. For ͷͲʹ individuals from the Cardiff collection in the UKͳͲK study, ͻͳͶ we acquired their pre-morbid )Q as extrapolated from National Adult Reading ͻͳͷ Test ȋNARTȌ, and identified Ͷͳʹ individuals for analysis after excluding all ͻͳ͸ individuals with predicted pre-morbid )Q of less than ͺͷ ȋor below one standard ͻͳ͹ deviation of the population distribution for )QȌ. We additionally acquired ͻͳͺ information on educational attainment in ͷͶ schizophrenia individuals in the ͻͳͻ UKͳͲK London collection, and retained ʹ͹ individuals without intellectual ͻʹͲ disability and who completed at least ͳʹ years of schooling. Lastly, the California ͻʹͳ Verbal Learning Test was conducted on ͳʹͶ Finnish schizophrenia individuals ͻʹʹ sequenced as part of UKͳͲK, and a composite score was generated from ͻʹ͵ measures of verbal and visual working memory, verbal abilities, ͻʹͶ visuoconstructive abilities, and processing speed. All individuals with intellectual ͻʹͷ disability had been excluded from cognitive testing. Within this set of samples, ͻʹ͸ we additionally excluded any individuals who ranked in the lowest decile in ͻʹ͹ CVLT composite score, and retained ͻʹ individuals for analysis. According to ͻʹͺ these criteria, we identified ͷ͵ͳ of ͸ͻ͹ schizophrenia individuals from the UK ͻʹͻ and Finnish data sets with cognitive data as not having intellectual disability. We ͻ͵Ͳ additionally acquired data on educational attainment for the Swedish ͻ͵ͳ schizophrenia cases and controls from the Swedish National Registry. After ͻ͵ʹ excluding individuals with intellectual disability, we identified ͳ,ͷʹ͹ ͻ͵͵ schizophrenia individuals who did not complete secondary school ȋless than ͳʹ ͻ͵Ͷ years of schoolingȌ, and ͸͵Ͷ schizophrenia individuals who completed at least ͻ͵ͷ compulsory and upper secondary schooling ȋat least ͳʹ years of schoolingȌ. The ͻ͵͸ last group with the greatest educational attainment and without intellectual ͻ͵͹ disability was defined as cases without cognitive impairment. )n the Swedish ͻ͵ͺ sample, Ͷͻ.Ͷ% of control samples had lower educational attainment than the ͻ͵ͻ ͸͵Ͷ individuals with schizophrenia defined as having no cognitive impairment, ͻͶͲ suggesting that our definition was sufficiently strict. )n total, combining the UK, ͻͶͳ Finnish, and Swedish data, we identified ͳ,ͳ͸ͷ schizophrenia individuals without ͻͶʹ cognitive impairment. ͻͶ͵ Using the variant threshold method, we tested for differences in rare LoF ͻͶͶ burden between the three case groups ȋintellectual disability, did not complete ͻͶͷ secondary school, no cognitive impairmentȌ against controls. We restricted these ͻͶ͸ analyses to three gene sets ȋLoF intolerant genes, genes in which LoF variants ͻͶ͹ are diagnostic for severe developmental disorders, and LoF intolerant genes ͻͶͺ after excluding severe developmental disorders genesȌ, and adjusted for multiple ͻͶͻ testing using Bonferroni correction ȋP  Ͳ.ͲͲ͵ͺ, or Ͳ.Ͳͷ/ͳ͵ testsȌ. ͻͷͲ Supplementary Table Ͷ enumerated all the statistical tests performed. To ͻͷͳ estimate the per-exome excess of rare singleton ȋdefined as having an allele ͻͷʹ count of one in our data setȌ LoF variants in cases compared to controls, we ͻͷ͵ regressed  ȋthe number of LoF variants in the gene set of interestȌ on case ͻͷͶ status ȋͲ or ͳȌ while controlling for  ȋthe total number of LoF variants ͻͷͷ 
genome-wideȌ and population ȋUK, Finnish, and SwedishȌ. The effect size and ͻͷ͸ ͻͷ% C) of the regression coefficient of case status predictor were reported.  ͻͷ͹ 
Data Availability ͻͷͺ  ͻͷͻ Sequence data and processed VCFs for the UKͳͲK project were deposited into ͻ͸Ͳ the European Genome-phenome Archive ȋEGAȌ under study accession code ͻ͸ͳ EGAOͲͲͲͲͲͲͲͲͲ͹ͻ. The processed VCFs from the Swedish case-control study ͻ͸ʹ were deposited in dbGAP under accession code ȋphsͲͲͲͶ͹͵.vͳ.pͳȌ. Rare variant ͻ͸͵ counts, and gene-level association results from combining the whole-exome ͻ͸Ͷ sequencing data sets were described in a previous publicationͳͺ and were made ͻ͸ͷ available on the PGC results and download page ͻ͸͸ ȋhttps://www.med.unc.edu/pgc/results-and-downloadsȌ. ͻ͸͹  ͻ͸ͺ 
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